MYC and MYCN Super-Enhancer Amplification and G-Quadruplex Transcriptional Regulation

The MYC proto-oncogene family comprises three paralogous basic helix-loop-helix leucine-zipper (bHLH-LZ) transcription factors: c-MYC (MYC, encoded on human chromosome 8q24.21 across 3 exons, 439 amino acids, ~49 kDa), N-MYC (MYCN, encoded on chromosome 2p24.3, 464 amino acids), and L-MYC (MYCL, encoded on chromosome 1p34.2, 364 amino acids). Monomeric MYC proteins are intrinsically disordered in solution and cannot bind DNA or activate transcription alone; biological activity requires obligate heterodimerization via their C-terminal bHLH-LZ domains with the small ubiquitous partner protein MAX (MYC-associated factor X, Chr14q23.3). The resulting MYC–MAX heterodimer recognizes canonical palindromic Enhancer-box (E-box, 5′-CACGTG-3′) and non-canonical (5′-CANNTG-3′) motifs at active promoters and enhancers, recruiting histone acetyltransferases (TRRAP–GCN5/TIP60) and Positive Transcription Elongation Factor b (P-TEFb, composed of CDK9 and Cyclin T1) to release paused RNA polymerase II (Pol II) and coordinate ribosome biogenesis across RNA Polymerases I, II, and III.

Somatic deregulation of MYC or MYCN—most commonly through focal gene amplification, chromosomal translocation (t(8;14) in Burkitt lymphoma), topological enhancer hijacking across the 8q24 gene desert, or extrachromosomal circular DNA (ecDNA) accumulation—occurs in >50% of human cancers, including high-risk neuroblastoma (MYCN), medulloblastoma, ovarian, breast, colorectal, and small-cell lung carcinomas. Because MYC expression is tightly buffered in normal diploid tissues (mRNA and protein half-lives t1/2 ≈ 20–30 minutes), its transcription is regulated upstream of the P1 and P2 promoters by the Nuclease Hypersensitive Element III₁ (NHE III1), a 27-nucleotide purine-rich sequence (Pu27) that folds into an intramolecular parallel G-quadruplex (G4) conformational silencer switch.

bHLH-LZ Coiled-Coil Heterodimerization and E-Box Recognition

In its unbound state, the C-terminal 90-residue bHLH-LZ region of MYC (residues 354–439) exists as a partially unfolded ensemble because electrostatic repulsion among conserved acidic and basic residues along the leucine-zipper heptad repeat prevents stable MYC–MYC homodimerization. Upon encountering MAX, coupled folding and binding generate a stable four-helix bundle (HLH) contiguous with a parallel two-stranded α-helical coiled-coil leucine zipper (Kd ≈ 10–50 nM), positioning the basic (b) α-helices of both subunits into the major groove of the 5′-CACGTG-3′ E-box. Specifically, conserved His359, Glu363, and Arg367 within the MYC basic region form direct hydrogen bonds with the central CpG and flanking purine bases, rendering MYC–MAX binding sensitive to CpG DNA methylation and nucleosome occupancy.

This proliferative axis is balanced by an antagonistic network of MAX-binding transcriptional repressors: MXD1 (MAD1), MXI1 (MAD2), MXD3, MXD4, and MNT, which compete with MYC for MAX heterodimerization and recruit the mSin3A/mSin3B–HDAC1/HDAC2 histone deacetylase corepressor complex via an N-terminal Sin3-Interaction Domain (SID) to deacetylate H3K27ac and silence E-box targets during cellular differentiation and quiescence.

MYC Boxes (MBI–MBIV), P-TEFb Pause Release, and Pol I/II/III Coordination

The N-terminal transactivation domain (TAD) and central region of MYC and MYCN contain six conserved sequence elements termed MYC Boxes (MB0, MBI, MBII, MBIIIa, MBIIIb, and MBIV) embedded within an intrinsically disordered polypeptide that partitions into phase-separated transcriptional condensates alongside BRD4 and Mediator:

1. MB0 and MBII (TRRAP and P-TEFb Recruitment): MBII (residues 128–143) directly binds TRRAP (transformation/transcription domain-associated protein), scaffolding the SAGA (GCN5) and NuA4 (TIP60) acetyltransferase complexes to acetylate H3 and H4 tails, while MB0 and the N-terminal TAD recruit P-TEFb (CDK9) to phosphorylate Ser2 of the RNA polymerase II C-terminal domain (CTD) and DSIF/NELF, triggering productive transcriptional elongation across virtually all active genes (global transcriptional amplification) alongside selective supralinear induction of metabolic and cell-cycle targets when MYC invades low-affinity enhancers at oncogenic expression levels.
2. MBI Phosphodegron (Thr58 and Ser62): Rapid turnover of MYC and MYCN (t1/2 ≈ 25 minutes) is governed by a sequential dual-kinase phosphodegron within MBI. Mitogenic ERK or CDK1 first phosphorylates Ser62 to stabilize MYC; subsequently, Glycogen Synthase Kinase 3β (GSK3β) phosphorylates Thr58, enabling the peptidyl-prolyl isomerase PIN1 and protein phosphatase PP2A to dephosphorylate Ser62 so the SCF^FBXW7 E3 ubiquitin ligase can recognize phospho-Thr58 and target MYC for 26S proteasomal destruction.
3. MBIIIb (WDR5 Chromatin Tethering): MBIIIb (residues 259–270) binds WDR5, a core subunit of MLL/COMPASS histone H3K4 methyltransferase complexes, anchoring MYC to active chromatin (H3K4me3) at ribosomal RNA (rRNA via Pol I), ribosomal protein (RP via Pol II), and tRNA/5S rRNA (via Pol III) genes to fuel protein translation.

The 8q24 Gene Desert, CTCF Insulation, and Extrachromosomal Circular DNA (ecDNA)

Unlike classical oncogenes activated by coding point mutations (except in Burkitt lymphoma, where APOBEC or AID somatic hypermutation hits the MBI Thr58 degron), MYC and MYCN in solid tumors encode wild-type polypeptides expressed at 10-fold to 200-fold elevated stoichiometric levels. The human MYC gene sits inside a ~3 Mb gene-poor topological domain on chromosome 8q24.21 flanked by lineage-specific super-enhancer (SE) clusters spanning hundreds of kilobases upstream (prostate, breast, and colorectal cancer CCAT1 enhancers) and up to 1.7 Mb downstream (the blood/leukemia enhancer cluster BENC and Notch-bound T-cell enhancers). Within the 3D nuclear architecture governed by CTCF and TAD insulation, a conserved promoter-proximal CTCF docking site immediately upstream of MYC anchors chromatin loop extrusion by cohesin, allowing diverse tissue-specific super-enhancers to loop into physical contact with the MYC promoter.

In ~25% of pediatric neuroblastomas and Subgroup 3 medulloblastomas, MYCN (or MYC) undergoes catastrophic chromosomal excision and circularization into acentric extrachromosomal circular DNA (ecDNA, "double minutes") ranging from 250 kb to >2 Mb in length. Because ecDNA molecules lack centromeres, they segregate unequally (non-Mendelian random partitioning) during mitosis, enabling tumors to accumulate 50 to 200 copies of MYCN co-amplified with adjacent local enhancers (e1–e5 on Chr2p24.3) within ultra-accessible, nucleosome-depleted circular chromatin hubs.

The NHE III1 Parallel G-Quadruplex (Pu27) Transcriptional Silencer

Approximately 85% to 90% of MYC transcription initiates from the P1 and P2 promoters, which are controlled directly by the Nuclease Hypersensitive Element III₁ (NHE III1) located -142 to -115 base pairs upstream of the P1 promoter. The non-template coding strand of NHE III1 contains a 27-nucleotide guanine-rich sequence (Pu27: 5′-TGGGGAGGGTGGGGAGGGTGGGGAAGG-3′, exhibiting a high G4Hunter score of 2.41) containing five contiguous guanine tracts (G-tracts) while the complementary template strand is cytosine-rich.

During active transcription, negative torsional supercoiling generated behind advancing RNA polymerase II melts the B-DNA duplex at NHE III1 (5′-GGGG-3′ / 5′-CCCC-3′). When unfolded as single-stranded DNA, the purine strand binds CNBP (ZNF9) and the pyrimidine strand binds hnRNP K, maintaining high-level MYC transcription. However, four of the five G-tracts within Pu27 can fold intramolecularly via Hoogsteen hydrogen bonding stabilized by central K⁺ ions (Tm > 85 °C in 100 mM K+) into a compact three-tetrad parallel-stranded G-quadruplex (MycG4, propeller loops of 1:2:1 nucleotides), while the opposite C-rich strand folds into an intercalated cytosine tetraplex (i-motif) under slightly acidic or crowded nuclear conditions. Formation of the NHE III1 G-quadruplex displaces CNBP/hnRNP K and Sp1, acting as a physical transcriptional silencer switch that shuts down 85–90% of MYC transcription until resolved by the nucleolar protein nucleolin (which stabilizes the G4 fold) versus the Non-Metastatic 2 (NM23-H2 / NDPK-B) factor and DHX36/RecQ helicases (which unfold the G4 back into transcriptionally active duplex DNA).

Dominant-Negative Miniproteins (Omomyc / OMO-103) and Super-Enhancer Dissolution

Because monomeric MYC lacks a globular hydrophobic ligand-binding pocket, direct small-molecule inhibition remained intractable for decades, motivating three structural and epigenetic bypass strategies in clinical drug discovery:

1. Omomyc (OMO-103) Dominant-Negative bHLH-LZ Miniprotein: Engineered by Laura Soucek via four targeted amino acid substitutions (Glu410Thr, Glu417Ile, Arg423Gln, Arg424Asn) within the leucine-zipper interface of MYC that eliminate electrostatic self-repulsion, the 91-residue cell-penetrating miniprotein Omomyc (OMO-103) forms stable Omomyc–Omomyc homodimers as well as Omomyc–MAX and Omomyc–MYC heterodimers. Because Omomyc lacks the N-terminal transactivation domain (MB0–MBII), Omomyc dimers competitively occupy 5′-CACGTG-3′ E-box sites across chromatin and sequester endogenous MYC away from DNA, completing Phase I clinical trials with target engagement and disease stabilization in solid tumors.
2. Super-Enhancer Condensate Dissolution and G4 Stabilization: Because MYC expression in amplified tumors relies on massive BRD4 and CDK9/CDK7 recruitment at 8q24 super-enhancers, bromodomain and extra-terminal (BET) inhibitors (JQ1, pelabresib) and CDK9 inhibitors selectively collapse MYC transcription, while G-quadruplex-stabilizing ligands (CX-5461, quarfloxin, APTO-253) lock the NHE III1 Pu27 silencer in its folded parallel G4 state.
3. Allosteric Destabilization of MYCN via Aurora A (AURKA): In MYCN-amplified neuroblastoma and neuroendocrine prostate cancer, Aurora Kinase A (AURKA) physically binds the N-terminus of MYCN during mitosis through a non-catalytic scaffolding interaction that shields MYCN from SCF^FBXW7-mediated ubiquitylation. Conformation-disrupting AURKA inhibitors (alisertib, CD532) and AURKA-directed PROTACs distort the AURKA N-terminal lobe (αC-helix), ejecting MYCN for rapid proteasomal degradation.

Why does MYC amplification on extrachromosomal circular DNA (ecDNA) accelerate drug resistance compared to chromosomal HSR amplification?

Chromosomal tandem duplications (homogeneously staining regions, HSRs) segregate symmetrically on sister chromatids during mitosis via centromeric spindle attachment, fixing copy number across daughter cells. By contrast, acentric ecDNA circles segregate randomly via chromosomal tethering, generating wide cell-to-cell copy-number variance within a single division cycle (binomial distribution). Under targeted therapy or chemotherapy, tumor populations rapidly shift their ecDNA distribution to select high-copy MYC/MYCN cells or transiently shed ecDNA to evade cytotoxic stress before re-expanding.

How does the 1:2:1 loop topology of the MYC NHE III1 G-quadruplex confer extreme thermodynamic stability?

Of the five guanine tracts in Pu27 (I–V), tracts II–V form the predominant physiologically relevant fold (Myc2345), comprising three stacked planar G-quartets linked by three single- or dinucleotide double-chain-reversal (propeller) loops of lengths 1 nt, 2 nt, and 1 nt. Because short 1-nt propeller loops (T or A) span the groove between adjacent parallel G-tracts with minimal entropic penalty, Myc2345 exhibits a thermal melting temperature (Tm) exceeding 85–90 °C at physiological K⁺ concentrations (~140 mM), requiring active DHX36 helicase ATP hydrolysis to unwind.

Why do MYC and MYCN behave as functionally interchangeable in development yet show distinct tumor tissue tropism?

Knock-in mouse experiments replacing the coding exons of endogenous Myc with Mycn rescue embryonic lethality and support normal development, demonstrating that their bHLH-LZ and MB0–MBIV domains execute shared biochemical functions. Their distinct cancer tissue distributions (MYCN in pediatric neural crest neuroblastoma, retinoblastoma, and medulloblastoma versus MYC in adult epithelial carcinomas and lymphomas) reflect the tissue-specific chromatin accessibility of the 2p24.3 neural super-enhancers versus the 8q24.21 epithelial/hematopoietic super-enhancer desert.

1. Siddiqui-Jain, A., Grand, C. L., Bearss, D. J., & Hurley, L. H. (2002). "Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription." Proceedings of the National Academy of Sciences, 99(18), 11593–11598. https://doi.org/10.1073/pnas.182256799
2. Lin, C. Y., Lovén, J., Rahl, P. B., et al. (2012). "Transcriptional amplification in tumor cells with elevated c-Myc." Cell, 151(1), 56–67. https://doi.org/10.1016/j.cell.2012.08.026
3. Helmsauer, K., Valieva, M. E., Ali, S., et al. (2020). "Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma." Nature Communications, 11(1), 5823. https://doi.org/10.1038/s41467-020-19452-y
4. Garralda, E., Beaulieu, M. E., Moreno, V., et al. (2024). "MYC targeting by OMO-103 in solid tumors: a phase 1 trial." Nature Medicine, 30(3), 762–771. https://doi.org/10.1038/s41591-024-02805-1